ArticleNPJ breast cancer2025

Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk.

Swarnavo Sarkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.